Chabacsin Research Institute Passes KOSDAQ Technical Special Case Technology Evaluation... Accelerates Listing Within the Year

Received Evaluation Report Grades A and BBB, Respectively

[Asia Economy Reporter Kim Ji-hee] Chabiontech affiliate Chavaccine Research Institute has passed the technology evaluation for KOSDAQ special technology listing. Based on this result, Chavaccine Research Institute plans to accelerate its KOSDAQ listing within this year.

Chavaccine Research Institute announced on the 11th that it received A grade and BBB grade respectively after a six-week evaluation of technology completeness, personnel level, and growth potential from the Korea Institute of Biotechnology and NICE Evaluation Information in January, thereby passing the technology evaluation.

The special technology listing system was introduced to provide listing opportunities to companies with excellent technology even if they do not meet profitability requirements for listing. Companies must obtain a BBB grade or higher from two technology evaluation agencies designated by the Korea Exchange, with at least one agency awarding an A grade. Companies that pass the technology evaluation are exempt from management and profitability criteria during the preliminary listing review process.

Passing this technology evaluation demonstrates Chavaccine Research Institute's technological capabilities and market growth value. In particular, the competitiveness of its proprietary immune-enhancing technology and related patents, as well as its differentiation in developing innovative vaccines such as premium vaccines, therapeutic vaccines, and anticancer vaccines, received positive evaluations.

Chavaccine Research Institute possesses specialized technology known as the immune adjuvant platform. The independently developed immune adjuvant 'L-pampo' can simultaneously induce humoral immune responses that activate antibody production by increasing antibody titers and cellular immune responses that eliminate virus-infected cells. Its effectiveness is significantly higher compared to other immune adjuvants that mainly function in humoral immunity. Utilizing this, Chavaccine Research Institute is conducting a Phase 2b clinical trial of its main pipeline, the chronic hepatitis B therapeutic vaccine ‘CVI-HBV-002’, and is also developing next-generation vaccines such as hepatitis B preventive vaccines, shingles, norovirus, and COVID-19 vaccines.

Since the preliminary listing review must be requested within six months after passing the technology evaluation, Chavaccine Research Institute plans to coordinate the schedule with its lead manager, Samsung Securities, and submit the preliminary review request as soon as possible. They intend to complete the preliminary listing review process quickly and finalize the KOSDAQ listing within this year.

Yeom Jeong-seon, CEO of Chavaccine Research Institute, stated, “We will swiftly proceed with the KOSDAQ listing to accelerate clinical trials and commercialization of our core pipelines and strategically expand investment in innovative new drug research and development. Based on our specialized immune adjuvant platform technology, we will diversify our pipelines and enhance corporate value.”

This content was produced with the assistance of AI translation services.